Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors (2021 edition)
-
Shi Guoming,
-
Huang Xiaoyong,
-
Ren Zhenggang,
-
Chen Yi,
-
Cheng Leilei,
-
Du Shisuo,
-
Fang Yi,
-
Ge Ningling,
-
Li Aimin,
-
Li Su,
-
Li Xiaomu,
-
Lu Qian,
-
Lu Pinxiang,
-
Sun Jianfang,
-
Wang Hanping,
-
Wei Lai,
-
Xu Li,
-
Yang Guohuan,
-
Zeng Zhaochong,
-
Zhang Lan,
-
Zhang Li,
-
Zhao Haitao,
-
Zhao Ling,
-
Zhao Ming,
-
Zhou Aiping,
-
Liu Rongle,
-
Liu Xinhui,
-
Wu Jiaming,
-
Zhang Ying,
-
Fan Jia,
-
Zhou Jian,
-
Oncology Chinese Society of
-
Graphical Abstract
-
Abstract
The clinical application of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of hepatocellular carcinoma (HCC) patients. With the widespread applica-tion of ICIs in HCC, the management of immune-related adverse events (irAE) gained more and more attention. However, the complicated disease characteristics and various combination therapies in HCC throw out challenges to irAE management. Therefore, the editorial board of the 'Chinese expert consensus on the management of immune-related adverse events of hepatocellular carcinoma treated with immune checkpoint inhibitors (2021 edition)' organizes multidisciplinary experts to discuss and formulate this consensus. The consensus focuses on issues related to HCC irAE manage-ment, and puts forward suggestions, in order to improve standardized and safety clinical medication, so as to maximize the benefits of immunotherapy for patients.
-
-
DownLoad: